-
EXCLUSIVE: DEA Stalling Hinders Critical Clinical Trials For Debilitating Conditions, Says MMJ BioPharma CEO
Thursday, September 12, 2024 - 3:58pm | 891MMJ BioPharma Cultivation finds itself at the center of a pivotal legal struggle with the Drug Enforcement Administration (DEA), accusing the agency of significant delays in processing its application to grow marijuana for pharmaceutical research. The company's lawsuit claims these delays have...
-
MMJ's THC-CBD Drug Ready For MS And Huntington's Disease Clinical Trials, Awaiting DEA And FDA Final Approvals
Friday, December 16, 2022 - 1:07pm | 376MMJ BioPharma Labs, MMJ BioPharma Cultivation and MMJ International Holdings in collaboration with a specialty pharmaceutical soft gelatin manufacturing company, has completed manufacturing of its THC, CBD capsule medicine formulated on compounds found in the cannabis plant. The company will...
-
MMJ BioPharma Cultivation Receives Marijuana Grow Equipment Creating Marijuana Center Of Excellence
Friday, July 8, 2022 - 7:56am | 407MMJ BioPharma Cultivation, a DEA API Bulk Manufacturer applicant to grow marijuana received their advanced precision cultivation equipment. With this innovative cultivation technology MMJ BioPharma Cultivation will be able to reproduce quality strain specific cannabis to meet the DEA's...
-
DEA Stonewalling MMJ's MS & Huntington's Disease Clinical Trials For 3 Years
Friday, June 10, 2022 - 9:18am | 744MMJ companies are building a center of marijuana excellence in Rhode Island and has filed for FDA sanctioned clinical trials in multiple sclerosis and Huntington's disease. MMJ was awarded the much coveted orphan drug designation from the FDA for its planned Huntington's disease trials, and...
-
'DEA Has Blown It Again' - MMJ Request Federal Court Action For Emergency Motion To Expedite
Thursday, May 5, 2022 - 9:29am | 535Megan Sheehan of Sheehan & Associates, Attorneys representing MMJ International Holdings and MMJ BioPharma Cultivation etal, scheduled to execute on clinical trials in Huntington's disease and multiple sclerosis, filed a motion in federal court against the Drug Enforcement Administration,...
-
MMJ BioPharma Cultivation To Produce Quality Cannabis, Meeting DEA's Definition Of Chemical Reproducibility
Tuesday, April 26, 2022 - 9:15pm | 614MMJ BioPharma Cultivation, a cannabis company, received its DEA schedule 1 Analytical Lab Registration, which allows for the international importation of cannabis for research and development. In addition, MMJ BioPharma has been awarded FDA “Orphan Designation” for its clinical trial in...
-
DEA Delays Production Of Marijuana Drug As Potential Treatment For Multiple Sclerosis And Huntington's Disease
Monday, March 14, 2022 - 8:02am | 363MMJ International Holdings, in collaboration with a specialty pharmaceutical solutions company, has been manufacturing gelatin capsule medicines based on compounds found in cannabis. The company will investigate these in clinical trials as potential treatments for multiple sclerosis (MS) and...